Last month, a drug company put out a press release claiming that an experimental drug had, for the first time, “unambiguously” slowed cognitive decline and brain damage in Alzheimer’s patients.
The drug ‘lecanemab’ – developed by Tokyo pharmaceutical company Eisai, and biotechnology firm Biogen in Cambridge, Massachusetts – is a monoclonal antibody that was said to remove clumps of amyloid proteins that are thought to kill brain cells and result in memory loss.
